Please ensure Javascript is enabled for purposes of website accessibility

Free Drugs!

By Brian Orelli, PhD – Updated Apr 6, 2017 at 2:06AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Pfizer's giving them away.

An economy that's causing consumers to cut back on everything -- including their medications -- and a bad public image thanks to skyrocketing medical costs has the pharmaceutical industry in a conundrum.

But Pfizer (NYSE:PFE) seems to have a solution for both problems: Give the stuff away. At least to people who have lost their jobs and health insurance recently and can show financial hardship. The program, announced last week, will cover more than 70 drugs, including Viagra. Yep, the erectile dysfunction drug is on the list -- insert your own joke here. 

The program is clearly a ploy to keep patients on Pfizer's drugs -- being on the drug for three months before becoming unemployed is a prerequisite. Pfizer is trying to avoid a situation where doctors might switch patients under financial hardship from a drug like Lipitor to a lower-cost generic statin like a knockoff of Merck's (NYSE:MRK) Zocor or Bristol-Myers Squibb's (NYSE:BMY) Pravachol. In that situation, when the job loss ends, many patients would likely stay on the generic rather than going back to the more expensive branded drug, especially if it seemed to be working.

The new program seems like a great move by Pfizer. It's providing excellent positive public relations and, considering the high margins on drugs, the program isn't likely to cost the company that much money -- Pfizer's employees have even volunteered to pick up some of the tab. I expect we'll see more pharmaceutical companies following suit with free or discount drugs: GlaxoSmithKline (NYSE:GSK) might have one in development, and I'd expect its European brethren, sanofi-aventis (NYSE:SNY) and AstraZeneca (NYSE:AZN) to follow suit.

More Foolishness:

Pfizer is a recommendation of the Inside Value newsletter. If you're interested in picking through the wreckage for possible turnaround candidates, you should have the Inside Value team on your side. Check it out for free with a 30-day trial.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$44.08 (-1.10%) $0.49
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$86.78 (-0.83%) $0.73
Sanofi Stock Quote
Sanofi
SNY
$38.40 (-1.87%) $0.73
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.58 (-3.07%) $-1.73
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$70.71 (-0.81%) $0.58
GSK Stock Quote
GSK
GSK
$29.36 (-2.17%) $0.65

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.